Health Canada PRCI

Three routes, and you can mix them: license TrialAssure ANONYMIZE® and run PRCI packages in-house, run it alongside TrialAssure® specialists, or hand us the submission as a fully outsourced package. Every route produces the deliverables Health Canada expects — annotated documents with readable proposed redactions, the Proposed Redaction Control Sheet (guidance Appendix E), and the anonymization report (Appendix F) recording methodology, threshold and residual risk. Accountability stays with the sponsor whichever you choose: Health Canada corresponds with the manufacturer and holds the final decision on what is published. Our specialists are PRCI-experienced — see services for how the models differ.

Same family, different regulator and process. PRCI is binding regulation — Food and Drug Regulations C.08.009.1–C.08.009.3 for drugs and Medical Devices Regulations ss. 43.11–43.13 for Class III and IV device applications, both in force since March 2019 — triggered by a final regulatory decision that can be positive or negative. EMA Policy 0070 is agency policy, centrally authorized medicines only, no devices, and its output sits behind a login while Health Canada’s portal is open access. The anonymization thinking is shared: both are risk-based with a documented report, and Health Canada’s encouraged 9% (0.09) threshold aligns with the threshold cited in EMA’s Policy 0070 External Guidance. The platform maps to both and tracks them side by side.

Quantified, risk-based anonymization of personal information, with the approach documented for Health Canada’s review. There is no fixed redaction list: you measure re-identification risk in context and transform only the variables that actually drive it, so the published documents stay analytically useful. Health Canada encourages a 9% (0.09) re-identification risk threshold — equivalent to a cell size of 11 patients — and expects an anonymization report (guidance Appendix F) setting out the method, the threshold applied and the residual-risk evidence. Blanket blacking-out and transformations without adequate justification get rejected, so the report carries as much weight as the redactions themselves.

Yes — PRCI applies to Class III and Class IV medical device licence applications and amendments; Class I and II devices are out of scope. The legal basis is Medical Devices Regulations sections 43.11–43.13, which mirror the drug provisions. Health Canada began proactive publication for devices in 2021; since December 2025, it publishes Class IV information proactively and Class III on request. Clinical information from past device applications has been available on request since March 20, 2019. Device manufacturers follow the same 120-day process, including anonymization and CBI justification.

120 calendar days from initiation to publication, per Health Canada’s PRCI guidance. Initiation is the final regulatory decision; the sponsor’s package — annotated documents, redaction control sheet, and anonymization report — is due 60 calendar days later. That 60-day window is the pinch point: anonymizing a full submission’s clinical study reports to a quantified 0.09 risk threshold is heavy work on a fixed clock, which is why sponsors run it through purpose-built software like TrialAssure ANONYMIZE or start preparation before the decision issues.

The sponsor gets exactly one additional opportunity to justify the redaction, and Health Canada retains final decision on what is published. The guidance lists the rejection grounds: the information supported the proposed conditions of use, the test or assay is not used exclusively by the manufacturer, the content was not shown to be out of scope, or it is already in the public domain. Data transformations lacking adequate justification are also rejected — every anonymization decision needs documented, quantified reasoning.

eCTD Modules 2.5 (clinical overviews), 2.7 (clinical summaries), and 5.3 (clinical study reports), plus three CSR appendices: 16.1.1 (protocol and amendments), 16.1.2 (sample case report forms), and 16.1.9 (statistical analysis plan). Individual patient listings and completed case report forms are out of scope and are not published. Final packages appear on Health Canada’s clinical information portal with a watermark and non-commercial Terms of Use — open access, unlike EMA’s login-gated clinical data website.

Yes. Health Canada’s guidance provides an alternative pathway: if the clinical information was already published under EMA Policy 0070, the sponsor may resubmit the EMA-accepted redacted documents with a certification (guidance Appendix G) attesting the content is identical. Where only part of the Canadian package went through EMA, sponsors redact just the outstanding components. Teams managing both jurisdictions typically track the paired obligations in TrialAssure so the certification pathway is identified at planning, not after day 60.

Anyone. Since March 20, 2019, members of the public can request clinical information from drug submissions and device applications that received a final decision before the regulations came into force, using an electronic form on Health Canada’s clinical information portal. The request identifies the product, manufacturer, indication, and documents sought. A granted request starts the same process for the sponsor — anonymization and CBI justification on Health Canada’s timeline — so long-approved products remain a live PRCI exposure.